Azenta Inc Dossier
Qualitative Analysis
Business overview
Azenta, Inc. (NASDAQ: AZTA) is a leading global provider of life sciences solutions, specializing in cold-chain sample management and multiomics services. The company operates through two primary segments: Sample Management Solutions, which provides automated storage systems, cryogenic systems, consumables, and repository services; and Multiomics, which delivers advanced genomic analysis services including next-generation sequencing and gene synthesis. Azenta serves top pharmaceutical and biotechnology companies, academic institutions, and healthcare organizations globally, enabling them to bring impactful breakthroughs and therapies to market faster.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A comprehensive transformation program designed to simplify the company's structure, rationalize physical sites, simplify the organization, and reduce operating costs.
Expected impact: Targeting $50 million in annualized cost savings to support Adjusted EBITDA margin expansion toward 20% and improve free cash flow conversion.
Deployment of the eco-friendly, high-density BioArc Ultra -80°C Automated Sample Storage System, which utilizes natural air-cooling technology instead of chemical refrigerants.
Expected impact: Expands automated storage capacity by 16 million samples per system, delivers up to 75% energy savings compared to manual freezers, and drives high-margin recurring product and service revenues.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Establishes a major European operational hub in Milton Keynes, UK, to support pharmaceutical, biotechnology, academic, and public health customers with high-capacity automated sample management and processing.
Financial impact: Expected to be dilutive to fiscal 2026 Adjusted EBITDA margin by approximately 35 basis points, but accretive to organic revenue growth and Adjusted EBITDA margin expansion in fiscal 2027 and 2028.
Strategic Partnerships
Aims to test and validate Azenta's sample management technologies (such as FluidX 0.26mL tubes) under extreme microgravity, launch, and spaceflight conditions aboard the SpaceLab Mk 2 platform during the EGGS-2 mission.
Terms: Terms of the collaboration were not publicly disclosed.